Keywords: sustiva-based, hiv, therapy, assessed, combination, dupont, pharma
Sustiva-based HIV therapy assessed
Article | 18 February 1999
Combination HIV therapy with DuPont Pharma's Sustiva (efavirenz) wasmore successful than combination therapy with Merck & Co's Crixivan (indinavir), according to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
